110 results on '"Darendeliler, E."'
Search Results
2. INVESTIGATION OF MIR-21, MIR-141 AND MIR-221 IN BLOOD CIRCULATION OF PATIENTS WITH PROSTATE CANCER: H51
- Author
-
Kovanclar, M, Yaman, F, Darendeliler, E, Dizdar, Y, Dalay, N, and Deligezer, U
- Published
- 2010
3. Primary spinal column sarcomas
- Author
-
Tasdemiroglu, E., Bagatur, E., Ayan, I., Darendeliler, E., and Patchell, R. A.
- Published
- 1996
- Full Text
- View/download PDF
4. Treatment outcomes of prostate cancer patients with Gleason score 8–10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study [Behandlungsergebnisse von mit definitiver Strahlentherapie behandelten Prostatakrebspatienten mit einem Gleason-Score von 8–10: TROD 09-001 Multizenterstudie]
- Author
-
Ozyigit G., Onal C., Igdem S., Alicikus Z.A., Iribas A., Akin M., Yalman D., Cetin I., Aksu M.G., Atalar B., Dincbas F., Hurmuz P., Guler O.C., Aydin B., Sert F., Yildirim C., Gorken I.B., Agaoglu F.Y., Korcum A.F., Yuce D., Ozkok S., Darendeliler E., Akyol F., and Ege Üniversitesi
- Subjects
Pelvic radiotherapy ,Grading system ,Hormonal treatment ,Intensity modulated radiation therapy ,Androgen deprivation therapy - Abstract
EgeUn###, Purpose: To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8–10 disease treated with external beam radiotherapy (EBRT)?+ androgen deprivation therapy (ADT) in the modern era. Methods: Institutional databases of biopsy proven 641 patients with GS 8–10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1–T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70?Gy total irradiation dose to prostate?± seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT. Results: The median follow-up time was 5.9 years (range 0.4–18.2 years); 5-year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (?78?Gy) and longer ADT duration (?2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9–10. Conclusions: Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9–10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving ‘non-optimal treatment’ (RT doses
- Published
- 2019
5. Bilateral Wilms Tumor, Demographic Characteristics, Treatment and Outcome: A Multicenter Study
- Author
-
Kebudi, R, Tugcu, D, Akici, F, Celkan, T, Vural, S, Tokuc, G, Darendeliler, E, Kebudi, R, Tugcu, D, Akici, F, Celkan, T, Vural, S, Tokuc, G, Darendeliler, E, and Yeditepe Üniversitesi
- Abstract
…
- Published
- 2017
6. The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
- Author
-
Akyol, F., Ozyigit, G., Onal, C., Igdem, S., Alicikus, Z. Arican, Iribas, A., Akin, M., YALMAN, DENİZ, Cetin, I., Aksu, M. G., Atalar, B., DİNÇBAŞ, Hidayet Fazilet, Darendeliler, E., Ozkok, S., Korcum, A. F., Agaoglu, F. Y., Gorken, I. B., Yildirim, C., SERT, FATMA, Aydin, B., Ege Üniversitesi, and Acibadem University Dspace
- Abstract
WOS: 000467786301348
- Published
- 2017
7. A Multicenter Evaluation of Nimotuzumab Containing Regimens for Paediatric Diffuse Intrinsic Pontine Gliomas
- Author
-
Kebudi, R., BANU CAKIR, Buyukkapu, S. Bay, Eker, N., Gorgun, O., Tokuc, G., Agaoglu, F. Yaman, Iribas, A., Darendeliler, E., and ÇAKIR, FATMA BETÜL
- Subjects
Kebudi R., Cakir B., Buyukkapu S. B. , Eker N., GÖRGÜN Ö. N. H. , Tokuc G., Agaoglu F. Y. , Iribas A., Darendeliler E., -A Multicenter Evaluation of Nimotuzumab Containing Regimens for Paediatric Diffuse Intrinsic Pontine Gliomas-, PEDIATRIC BLOOD & CANCER, cilt.63, 2016 - Published
- 2016
8. CHILDHOOD EWING SARCOMA FAMILY TUMORS: 25-YEAR EXPERIENCE OF A SINGLE CENTER IN TURKEY
- Author
-
Kebudi, R., Gorgun, O., ÇAKIR, FATMA BETÜL, Agaoglu, F. Yaman, Bay, S. Buyukkapu, Koc, B., Zulfikar, B., Ozger, H., Ayan, I., Darendeliler, E., and ÇAKIR, FATMA BETÜL
- Subjects
25-YEAR EXPERIENCE OF A SINGLE CENTER IN TURKEY-, PEDIATRIC BLOOD & CANCER, cilt.62, 2015 [Kebudi R., Gorgun O., ÇAKIR F. B. , Agaoglu F. Y. , Bay S. B. , Koc B., Zulfikar B., Ozger H., Ayan I., Darendeliler E., -CHILDHOOD EWING SARCOMA FAMILY TUMORS] - Published
- 2015
9. PO-0734: The effect of TAB duration and pelvic RT in prostate cancers with gleason score 8-10: TROG study
- Author
-
Ozyigit, G., primary, Onal, C., additional, Igdem, S., additional, Arican Alicikus, Z., additional, Iribas, A., additional, Akin, M., additional, Yalman, D., additional, Cetin, I., additional, Aksu, M.G., additional, Atalar, B., additional, Dincbas, F., additional, Aydin, B., additional, Sert, F., additional, Yildirim, C., additional, Gorken, I.B., additional, Agaoglu, F.Y., additional, Korcum, A.F., additional, Ozkok, S., additional, Darendeliler, E., additional, and Akyol, F., additional
- Published
- 2017
- Full Text
- View/download PDF
10. PINEALOBLASTOMAS
- Author
-
Kebudi, R., Koc, B., Agaoglu, F. Yaman, Gorgun, O., Wolff, J., Kapu, S. Bay, Kebudi, A., Darendeliler, E., and Maltepe Üniversitesi
- Abstract
WOS: 000343932100726, …
- Published
- 2014
11. PO-0750: Conventionally-fractionated VMAT vs. SBRT in prostate cancer:PSA kinetics, toxicity,quality of life
- Author
-
Tambas, M., primary, Agaoglu, F., additional, Iribas, A., additional, Guveli, M., additional, Dizdar, Y., additional, Okutan, M., additional, Ozkan, D., additional, Tenekeci, N., additional, and Darendeliler, E., additional
- Published
- 2016
- Full Text
- View/download PDF
12. INTRAOCULAR RETINOBLASTOMA: 20-YEARS EXPERIENCE OF A SINGLE CENTER
- Author
-
Kebudi, R., Tuncer, S., ÇAKIR, FATMA BETÜL, Gorgun, O., Aksu, N., Ayan, I., Agaoglu, F. Y., Darendeliler, E., Dizdar, Y., Peksayar, G., and ÇAKIR, FATMA BETÜL
- Subjects
20-YEARS EXPERIENCE OF A SINGLE CENTER-, PEDIATRIC BLOOD & CANCER, cilt.60, ss.126, 2013 [Kebudi R., Tuncer S., ÇAKIR F. B. , Gorgun O., Aksu N., Ayan I., Agaoglu F. Y. , Darendeliler E., Dizdar Y., Peksayar G., -INTRAOCULAR RETINOBLASTOMA] - Published
- 2013
13. EXTRACRANIAL GERM CELL TUMORS IN CHILDREN: 23-YR EXPERIENCE OF A SINGLE CENTER
- Author
-
Kebudi, R., ÇAKIR, FATMA BETÜL, Gorgun, O., Uludag, D., Ayan, I., Zulfikar, B., Agaoglu, F. Y., Darendeliler, E., and ÇAKIR, FATMA BETÜL
- Subjects
23-YR EXPERIENCE OF A SINGLE CENTER-, PEDIATRIC BLOOD & CANCER, cilt.60, ss.101, 2013 [Kebudi R., ÇAKIR F. B. , Gorgun O., Uludag D., Ayan I., Zulfikar B., Agaoglu F. Y. , Darendeliler E., -EXTRACRANIAL GERM CELL TUMORS IN CHILDREN] - Published
- 2013
14. EP-1610: Twelve years treatment results of LDR brachytherapy for prostate cancer in Turkey
- Author
-
Aslay, I., primary, Kemikler, G., additional, Küçücük, S., additional, Akinci, M., additional, Ozveri, H., additional, Ozbay, I., additional, Senkesen, O., additional, Küçücük, H., additional, Esen, T., additional, Agaoglu, F., additional, Tenekeci, N., additional, and Darendeliler, E., additional
- Published
- 2015
- Full Text
- View/download PDF
15. ED-11 * DEMOGRAPHIC, CLINICAL AND SURVIVAL FEATURES OF CHILDHOOD CENTRAL NERVOUS SYSTEM TUMORS IN ISTANBUL UNIVERSITY, ONCOLOGY INSTITUTE DURING 22 YEARS (1990-2012)
- Author
-
Kebudi, R., primary, Darendeliler, E., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Uludag, D., additional, and Ayan, I., additional
- Published
- 2014
- Full Text
- View/download PDF
16. PT-07 * PINEALOBLASTOMAS
- Author
-
Kebudi, R., primary, Koc, B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Wolff, J., additional, Kapu, S. B., additional, Kebudi, A., additional, Cak r, F. B., additional, and Darendeliler, E., additional
- Published
- 2014
- Full Text
- View/download PDF
17. Bladder Preservation Therapy for Muscle Invasive Bladder Cancer
- Author
-
Agaoglu, F., primary, Iribas, A., additional, Ozkurt, S., additional, Basaran, M., additional, Darendeliler, E., additional, Dizdar, Y., additional, Tunc, M., additional, and Ozcan, F., additional
- Published
- 2014
- Full Text
- View/download PDF
18. MEDULLOBLASTOMA
- Author
-
Vaidyanathan, G., primary, Gururangan, S., additional, Bigner, D., additional, Zalutsky, M., additional, Morfouace, M., additional, Shelat, A., additional, Megan, J., additional, Freeman, B. B., additional, Robinson, S., additional, Throm, S., additional, Olson, J. M., additional, Li, X.-N., additional, Guy, K. R., additional, Robinson, G., additional, Stewart, C., additional, Gajjar, A., additional, Roussel, M., additional, Sirachainan, N., additional, Pakakasama, S., additional, Anurathapan, U., additional, Hansasuta, A., additional, Dhanachai, M., additional, Khongkhatithum, C., additional, Hongeng, S., additional, Feroze, A., additional, Lee, K.-S., additional, Gholamin, S., additional, Wu, Z., additional, Lu, B., additional, Mitra, S., additional, Cheshier, S., additional, Northcott, P., additional, Lee, C., additional, Zichner, T., additional, Lichter, P., additional, Korbel, J., additional, Wechsler-Reya, R., additional, Pfister, S., additional, Project, I. P. T., additional, Li, K. K.-W., additional, Xia, T., additional, Ma, F. M. T., additional, Zhang, R., additional, Zhou, L., additional, Lau, K.-M., additional, Ng, H.-K., additional, Lafay-Cousin, L., additional, Chi, S., additional, Madden, J., additional, Smith, A., additional, Wells, E., additional, Owens, E., additional, Strother, D., additional, Foreman, N., additional, Packer, R., additional, Bouffet, E., additional, Wataya, T., additional, Peacock, J., additional, Taylor, M. D., additional, Ivanov, D., additional, Garnett, M., additional, Parker, T., additional, Alexander, C., additional, Meijer, L., additional, Grundy, R., additional, Gellert, P., additional, Ashford, M., additional, Walker, D., additional, Brent, J., additional, Cader, F. Z., additional, Ford, D., additional, Kay, A., additional, Walsh, R., additional, Solanki, G., additional, Peet, A., additional, English, M., additional, Shalaby, T., additional, Fiaschetti, G., additional, Baulande, S., additional, Gerber, N., additional, Baumgartner, M., additional, Grotzer, M., additional, Hayase, T., additional, Kawahara, Y., additional, Yagi, M., additional, Minami, T., additional, Kanai, N., additional, Yamaguchi, T., additional, Gomi, A., additional, Morimoto, A., additional, Hill, R., additional, Kuijper, S., additional, Lindsey, J., additional, Schwalbe, E., additional, Barker, K., additional, Boult, J., additional, Williamson, D., additional, Ahmad, Z., additional, Hallsworth, A., additional, Ryan, S., additional, Poon, E., additional, Ruddle, R., additional, Raynaud, F., additional, Howell, L., additional, Kwok, C., additional, Joshi, A., additional, Nicholson, S. L., additional, Crosier, S., additional, Wharton, S., additional, Robson, K., additional, Michalski, A., additional, Hargrave, D., additional, Jacques, T., additional, Pizer, B., additional, Bailey, S., additional, Swartling, F., additional, Petrie, K., additional, Weiss, W., additional, Chesler, L., additional, Clifford, S., additional, Kitanovski, L., additional, Prelog, T., additional, Kotnik, B. F., additional, Debeljak, M., additional, Grotzer, M. A., additional, Gevorgian, A., additional, Morozova, E., additional, Kazantsev, I., additional, Iukhta, T., additional, Safonova, S., additional, Kumirova, E., additional, Punanov, Y., additional, Afanasyev, B., additional, Zheludkova, O., additional, Grajkowska, W., additional, Pronicki, M., additional, Cukrowska, B., additional, Dembowska-Baginska, B., additional, Lastowska, M., additional, Murase, A., additional, Nobusawa, S., additional, Gemma, Y., additional, Yamazaki, F., additional, Masuzawa, A., additional, Uno, T., additional, Osumi, T., additional, Shioda, Y., additional, Kiyotani, C., additional, Mori, T., additional, Matsumoto, K., additional, Ogiwara, H., additional, Morota, N., additional, Hirato, J., additional, Nakazawa, A., additional, Terashima, K., additional, Fay-McClymont, T., additional, Walsh, K., additional, Mabbott, D., additional, Sturm, D., additional, Northcott, P. A., additional, Jones, D. T. W., additional, Korshunov, A., additional, Pfister, S. M., additional, Kool, M., additional, Hooper, C., additional, Hawes, S., additional, Kees, U., additional, Gottardo, N., additional, Dallas, P., additional, Siegfried, A., additional, Bertozzi, A. I., additional, Sevely, A., additional, Loukh, N., additional, Munzer, C., additional, Miquel, C., additional, Bourdeaut, F., additional, Pietsch, T., additional, Dufour, C., additional, Delisle, M. B., additional, Kawauchi, D., additional, Rehg, J., additional, Finkelstein, D., additional, Zindy, F., additional, Phoenix, T., additional, Gilbertson, R., additional, Trubicka, J., additional, Borucka-Mankiewicz, M., additional, Ciara, E., additional, Chrzanowska, K., additional, Perek-Polnik, M., additional, Abramczuk-Piekutowska, D., additional, Jurkiewicz, D., additional, Luczak, S., additional, Kowalski, P., additional, Krajewska-Walasek, M., additional, Sheila, C., additional, Lee, S., additional, Foster, C., additional, Manoranjan, B., additional, Pambit, M., additional, Berns, R., additional, Fotovati, A., additional, Venugopal, C., additional, O'Halloran, K., additional, Narendran, A., additional, Hawkins, C., additional, Ramaswamy, V., additional, Taylor, M., additional, Singhal, A., additional, Hukin, J., additional, Rassekh, R., additional, Yip, S., additional, Singh, S., additional, Duhman, C., additional, Dunn, S., additional, Chen, T., additional, Rush, S., additional, Fuji, H., additional, Ishida, Y., additional, Onoe, T., additional, Kanda, T., additional, Kase, Y., additional, Yamashita, H., additional, Murayama, S., additional, Nakasu, Y., additional, Kurimoto, T., additional, Kondo, A., additional, Sakaguchi, S., additional, Fujimura, J., additional, Saito, M., additional, Arakawa, T., additional, Arai, H., additional, Shimizu, T., additional, Jurkiewicz, E., additional, Daszkiewicz, P., additional, Drogosiewicz, M., additional, Hovestadt, V., additional, Buchhalter, I., additional, Jager, N. N., additional, Stuetz, A., additional, Johann, P., additional, Schmidt, C., additional, Ryzhova, M., additional, Landgraf, P., additional, Hasselblatt, M., additional, Schuller, U., additional, Yaspo, M.-L., additional, von Deimling, A., additional, Eils, R., additional, Modi, A., additional, Patel, M., additional, Berk, M., additional, Wang, L.-x., additional, Plautz, G., additional, Camara-Costa, H., additional, Resch, A., additional, Lalande, C., additional, Kieffer, V., additional, Poggi, G., additional, Kennedy, C., additional, Bull, K., additional, Calaminus, G., additional, Grill, J., additional, Doz, F., additional, Rutkowski, S., additional, Massimino, M., additional, Kortmann, R.-D., additional, Lannering, B., additional, Dellatolas, G., additional, Chevignard, M., additional, Solecki, D., additional, McKinnon, P., additional, Olson, J., additional, Hayden, J., additional, Ellison, D., additional, Buss, M., additional, Remke, M., additional, Lee, J., additional, Caspary, T., additional, Castellino, R., additional, Sabel, M., additional, Gustafsson, G., additional, Fleischhack, G., additional, Benesch, M., additional, Navajas, A., additional, Reddingius, R., additional, Delisle, M.-B., additional, Lafon, D., additional, Sevenet, N., additional, Pierron, G., additional, Delattre, O., additional, Ecker, J., additional, Oehme, I., additional, Mazitschek, R., additional, Lodrini, M., additional, Deubzer, H. E., additional, Kulozik, A. E., additional, Witt, O., additional, Milde, T., additional, Patmore, D., additional, Boulos, N., additional, Wright, K., additional, Boop, S., additional, Janicki, T., additional, Burzynski, S., additional, Burzynski, G., additional, Marszalek, A., additional, Triscott, J., additional, Green, M., additional, Rassekh, S. R., additional, Toyota, B., additional, Dunham, C., additional, Dunn, S. E., additional, Liu, K.-W., additional, Pei, Y., additional, Genovesi, L., additional, Ji, P., additional, Davis, M., additional, Ng, C. G., additional, Cho, Y.-J., additional, Jenkins, N., additional, Copeland, N., additional, Wainwright, B., additional, Tang, Y., additional, Schubert, S., additional, Nguyen, B., additional, Masoud, S., additional, Lee, A., additional, Willardson, M., additional, Bandopadhayay, P., additional, Bergthold, G., additional, Atwood, S., additional, Whitson, R., additional, Qi, J., additional, Beroukhim, R., additional, Tang, J., additional, Oro, A., additional, Link, B., additional, Bradner, J., additional, Vallero, S. G., additional, Bertin, D., additional, Basso, M. E., additional, Milanaccio, C., additional, Peretta, P., additional, Cama, A., additional, Mussano, A., additional, Barra, S., additional, Morana, G., additional, Morra, I., additional, Nozza, P., additional, Fagioli, F., additional, Garre, M. L., additional, Darabi, A., additional, Sanden, E., additional, Visse, E., additional, Stahl, N., additional, Siesjo, P., additional, Vaka, D., additional, Vasquez, F., additional, Weir, B., additional, Cowley, G., additional, Keller, C., additional, Hahn, W., additional, Gibbs, I. C., additional, Partap, S., additional, Yeom, K., additional, Martinez, M., additional, Vogel, H., additional, Donaldson, S. S., additional, Fisher, P., additional, Perreault, S., additional, Guerrini-Rousseau, L., additional, Pujet, S., additional, Kieffer-Renaux, V., additional, Raquin, M. A., additional, Varlet, P., additional, Longaud, A., additional, Sainte-Rose, C., additional, Valteau-Couanet, D., additional, Staal, J., additional, Lau, L. S., additional, Zhang, H., additional, Ingram, W. J., additional, Cho, Y. J., additional, Hathout, Y., additional, Brown, K., additional, Rood, B. R., additional, Handler, M., additional, Hankinson, T., additional, Kleinschmidt-Demasters, B. K., additional, Hutter, S., additional, Jones, D. T., additional, Kagawa, N., additional, Hirayama, R., additional, Kijima, N., additional, Chiba, Y., additional, Kinoshita, M., additional, Takano, K., additional, Eino, D., additional, Fukuya, S., additional, Yamamoto, F., additional, Nakanishi, K., additional, Hashimoto, N., additional, Hashii, Y., additional, Hara, J., additional, Yoshimine, T., additional, Wang, J., additional, Guo, C., additional, Yang, Q., additional, Chen, Z., additional, Filipek, I., additional, Swieszkowska, E., additional, Tarasinska, M., additional, Perek, D., additional, Kebudi, R., additional, Koc, B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Wolff, J., additional, Darendeliler, E., additional, Kerl, K., additional, Gronych, J., additional, McGlade, J., additional, Endersby, R., additional, Hii, H., additional, Johns, T., additional, Sastry, J., additional, Murphy, D., additional, Ronghe, M., additional, Cunningham, C., additional, Cowie, F., additional, Jones, R., additional, Calisto, A., additional, Sangra, M., additional, Mathieson, C., additional, Brown, J., additional, Phuakpet, K., additional, Larouche, V., additional, Bartels, U., additional, Ishida, T., additional, Hasegawa, D., additional, Miyata, K., additional, Ochi, S., additional, Saito, A., additional, Kozaki, A., additional, Yanai, T., additional, Kawasaki, K., additional, Yamamoto, K., additional, Kawamura, A., additional, Nagashima, T., additional, Akasaka, Y., additional, Soejima, T., additional, Yoshida, M., additional, Kosaka, Y., additional, von Bueren, A., additional, Goschzik, T., additional, Kortmann, R., additional, von Hoff, K., additional, Friedrich, C., additional, Muehlen, A. z., additional, Warmuth-Metz, M., additional, Soerensen, N., additional, Deinlein, F., additional, Zwiener, I., additional, Faldum, A., additional, Kuehl, J., additional, KRAMER, K., additional, -Taskar, N. P., additional, Zanzonico, P., additional, Humm, J. L., additional, Wolden, S. L., additional, Cheung, N.-K. V., additional, Venkataraman, S., additional, Alimova, I., additional, Harris, P., additional, Birks, D., additional, Balakrishnan, I., additional, Griesinger, A., additional, Foreman, N. K., additional, Vibhakar, R., additional, Margol, A., additional, Robison, N., additional, Gnanachandran, J., additional, Hung, L., additional, Kennedy, R., additional, Vali, M., additional, Dhall, G., additional, Finlay, J., additional, Erdrich-Epstein, A., additional, Krieger, M., additional, Drissi, R., additional, Fouladi, M., additional, Gilles, F., additional, Judkins, A., additional, Sposto, R., additional, Asgharzadeh, S., additional, Peyrl, A., additional, Chocholous, M., additional, Holm, S., additional, Grillner, P., additional, Blomgren, K., additional, Azizi, A., additional, Czech, T., additional, Gustafsson, B., additional, Dieckmann, K., additional, Leiss, U., additional, Slavc, I., additional, Babelyan, S., additional, Dolgopolov, I., additional, Pimenov, R., additional, Mentkevich, G., additional, Gorelishev, S., additional, Laskov, M., additional, von Bueren, A. O., additional, Nowak, J., additional, Kortmann, R. D., additional, Mynarek, M., additional, Muller, K., additional, Gerber, N. U., additional, Ottensmeier, H., additional, Kwiecien, R., additional, Yankelevich, M., additional, Boyarshinov, V., additional, Glekov, I., additional, Ozerov, S., additional, Gorelyshev, S., additional, Popa, A., additional, Subbotina, N., additional, Martin, A. M., additional, Nirschl, C., additional, Polanczyk, M., additional, Bell, R., additional, Martinez, D., additional, Sullivan, L. M., additional, Santi, M., additional, Burger, P. C., additional, Taube, J. M., additional, Drake, C. G., additional, Pardoll, D. M., additional, Lim, M., additional, Li, L., additional, Wang, W.-G., additional, Pu, J.-X., additional, Sun, H.-D., additional, Ruggieri, R., additional, Symons, M. H., additional, Vanan, M. I., additional, Bolin, S., additional, Schumacher, S., additional, Zeid, R., additional, Yu, F., additional, Vue, N., additional, Gibson, W., additional, Paolella, B., additional, Swartling, F. J., additional, Kieran, M. W., additional, Bradner, J. E., additional, Maher, O., additional, Khatua, S., additional, Tarek, N., additional, Zaky, W., additional, Gupta, T., additional, Mohanty, S., additional, Kannan, S., additional, Jalali, R., additional, Kapitza, E., additional, Denkhaus, D., additional, Muhlen, A. z., additional, van Vuurden, D. G., additional, Garami, M., additional, Fangusaro, J., additional, Davidson, T. B., additional, da Costa, M. J. G., additional, Sterba, J., additional, Clifford, S. C., additional, Finlay, J. L., additional, Schmidt, R., additional, Felsberg, J., additional, Skladny, H., additional, Cremer, F., additional, Reifenberger, G., additional, Kunder, R., additional, Sridhar, E., additional, Moiyadi, A. A., additional, Goel, A., additional, Goel, N., additional, Shirsat, N., additional, Othman, R., additional, Storer, L., additional, Kerr, I., additional, Coyle, B., additional, Law, N., additional, Smith, M. L., additional, Greenberg, M., additional, Laughlin, S., additional, Malkin, D., additional, Liu, F., additional, Moxon-Emre, I., additional, Scantlebury, N., additional, Nasir, A., additional, Onion, D., additional, Lourdusamy, A., additional, Grabowska, A., additional, Cai, Y., additional, Bradshaw, T., additional, de Medeiros, R. S. S., additional, Beaugrand, A., additional, Soares, S., additional, Epelman, S., additional, Wang, W., additional, Sultan, M., additional, Wechsler-Reya, R. J., additional, Zapatka, M., additional, Radlwimmer, B., additional, Alderete, D., additional, Baroni, L., additional, Lubinieki, F., additional, Auad, F., additional, Gonzalez, M. L., additional, Puya, W., additional, Pacheco, P., additional, Aurtenetxe, O., additional, Gaffar, A., additional, Gros, L., additional, Cruz, O., additional, Calvo, C., additional, Shinojima, N., additional, Nakamura, H., additional, Kuratsu, J.-i., additional, Hanaford, A., additional, Eberhart, C., additional, Archer, T., additional, Tamayo, P., additional, Pomeroy, S., additional, Raabe, E., additional, De Braganca, K., additional, Gilheeney, S., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Dunkel, I., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Shih, D., additional, Wang, X., additional, Faria, C., additional, Raybaud, C., additional, Tabori, U., additional, Rutka, J., additional, Jacobs, S., additional, De Vathaire, F., additional, Diallo, I., additional, Llanas, D., additional, Verez, C., additional, Diop, F., additional, Kahlouche, A., additional, Puget, S., additional, Thompson, E., additional, Prince, E., additional, Amani, V., additional, Sin-Chan, P., additional, Lu, M., additional, Kleinman, C., additional, Spence, T., additional, Picard, D., additional, Ho, K. C., additional, Chan, J., additional, Majewski, J., additional, Jabado, N., additional, Dirks, P., additional, Huang, A., additional, Madden, J. R., additional, Donson, A. M., additional, Mirsky, D. M., additional, Dubuc, A., additional, Mack, S., additional, Gendoo, D., additional, Luu, B., additional, MacDonald, T., additional, Van Meter, T., additional, Croul, S., additional, Laureano, A., additional, Brugmann, W., additional, Denman, C., additional, Singh, H., additional, Huls, H., additional, Moyes, J., additional, Sandberg, D., additional, Silla, L., additional, Cooper, L., additional, and Lee, D., additional
- Published
- 2014
- Full Text
- View/download PDF
19. HIGH GRADE GLIOMAS AND DIPG
- Author
-
Classen, C. F., primary, William, D., additional, Linnebacher, M., additional, Farhod, A., additional, Kedr, W., additional, Elsabe, B., additional, Fadel, S., additional, Van Gool, S., additional, De Vleeschouwer, S., additional, Koks, C., additional, Garg, A., additional, Ehrhardt, M., additional, Riva, M., additional, Agostinis, P., additional, Graf, N., additional, Yao, T.-W., additional, Yoshida, Y., additional, Zhang, J., additional, Ozawa, T., additional, James, D., additional, Nicolaides, T., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Al-Kofide, A., additional, Al-Shail, E., additional, Khafaga, Y., additional, Al-Hindi, H., additional, Dababo, M., additional, Haq, A. U., additional, Anas, M., additional, Barria, M. G., additional, Siddiqui, K., additional, Hassounah, M., additional, Ayas, M., additional, van Zanten, S. V., additional, Jansen, M., additional, van Vuurden, D., additional, Huisman, M., additional, Vugts, D., additional, Hoekstra, O., additional, van Dongen, G., additional, Kaspers, G., additional, Cockle, J., additional, Ilett, E., additional, Scott, K., additional, Bruning-Richardson, A., additional, Picton, S., additional, Short, S., additional, Melcher, A., additional, Benesch, M., additional, Warmuth-Metz, M., additional, von Bueren, A. O., additional, Hoffmann, M., additional, Pietsch, T., additional, Kortmann, R.-D., additional, Eyrich, M., additional, Rutkowski, S., additional, Fruhwald, M. C., additional, Faber, J., additional, Kramm, C., additional, Porkholm, M., additional, Valanne, L., additional, Lonnqvist, T., additional, Holm, S., additional, Lannering, B., additional, Riikonen, P., additional, Wojcik, D., additional, Sehested, A., additional, Clausen, N., additional, Harila-Saari, A., additional, Schomerus, E., additional, Thorarinsdottir, H. K., additional, Lahteenmaki, P., additional, Arola, M., additional, Thomassen, H., additional, Saarinen-Pihkala, U. M., additional, Kivivuori, S.-M., additional, Buczkowicz, P., additional, Hoeman, C., additional, Rakopoulos, P., additional, Pajovic, S., additional, Morrison, A., additional, Bouffet, E., additional, Bartels, U., additional, Becher, O., additional, Hawkins, C., additional, Gould, T. W. A., additional, Rahman, C. V., additional, Smith, S. J., additional, Barrett, D. A., additional, Shakesheff, K. M., additional, Grundy, R. G., additional, Rahman, R., additional, Barua, N., additional, Cronin, D., additional, Gill, S., additional, Lowisl, S., additional, Hochart, A., additional, Maurage, C.-A., additional, Rocourt, N., additional, Vinchon, M., additional, Kerdraon, O., additional, Escande, F., additional, Grill, J., additional, Pick, V. K., additional, Leblond, P., additional, Burzynski, G., additional, Janicki, T., additional, Burzynski, S., additional, Marszalek, A., additional, Ramani, N., additional, Zaky, W., additional, Kannan, G., additional, Morani, A., additional, Sandberg, D., additional, Ketonen, L., additional, Maher, O., additional, Corrales-Medina, F., additional, Meador, H., additional, Khatua, S., additional, Brassesco, M., additional, Delsin, L., additional, Roberto, G., additional, Silva, C., additional, Ana, L., additional, Rego, E., additional, Scrideli, C., additional, Umezawa, K., additional, Tone, L., additional, Kim, S. J., additional, Kim, C.-Y., additional, Kim, I.-A., additional, Han, J. H., additional, Choi, B.-S., additional, Ahn, H. S., additional, Choi, H. S., additional, Haque, F., additional, Layfield, R., additional, Grundy, R., additional, Gandola, L., additional, Pecori, E., additional, Biassoni, V., additional, Schiavello, E., additional, Chiruzzi, C., additional, Spreafico, F., additional, Modena, P., additional, Bach, F., additional, Pignoli, E., additional, Massimino, M., additional, Drogosiewicz, M., additional, Dembowska-Baginska, B., additional, Jurkiewicz, E., additional, Filipek, I., additional, Perek-Polnik, M., additional, Swieszkowska, E., additional, Perek, D., additional, Bender, S., additional, Jones, D. T., additional, Warnatz, H.-J., additional, Hutter, B., additional, Zichner, T., additional, Gronych, J., additional, Korshunov, A., additional, Eils, R., additional, Korbel, J. O., additional, Yaspo, M.-L., additional, Lichter, P., additional, Pfister, S. M., additional, Yadavilli, S., additional, Becher, O. J., additional, Kambhampati, M., additional, Packer, R. J., additional, Nazarian, J., additional, Lechon, F. C., additional, Fowkes, L., additional, Khabra, K., additional, Martin-Retortillo, L. M., additional, Marshall, L. V., additional, Vaidya, S., additional, Koh, D.-M., additional, Leach, M. O., additional, Pearson, A. D., additional, Zacharoulis, S., additional, Schrey, D., additional, Barone, G., additional, Panditharatna, E., additional, Stampar, M., additional, Siu, A., additional, Gordish-Dressman, H., additional, Devaney, J., additional, Hwang, E. I., additional, Chung, A. H., additional, Mittapalli, R. K., additional, Elmquist, W. F., additional, Castel, D., additional, Debily, M.-A., additional, Philippe, C., additional, Truffaux, N., additional, Taylor, K., additional, Calmon, R., additional, Boddaert, N., additional, Le Dret, L., additional, Saulnier, P., additional, Lacroix, L., additional, Mackay, A., additional, Jones, C., additional, Puget, S., additional, Sainte-Rose, C., additional, Blauwblomme, T., additional, Varlet, P., additional, Entz-Werle, N., additional, Maugard, C., additional, Bougeard, G., additional, Nguyen, A., additional, Chenard, M. P., additional, Schneider, A., additional, Gaub, M. P., additional, Tsoli, M., additional, Vanniasinghe, A., additional, Luk, P., additional, Dilda, P., additional, Haber, M., additional, Hogg, P., additional, Ziegler, D., additional, Simon, S., additional, Monje, M., additional, Gurova, K., additional, Gudkov, A., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Zamecnik, J., additional, Kyncl, M., additional, Tichy, M., additional, Puchmajerova, A., additional, Stary, J., additional, Sumerauer, D., additional, Boult, J., additional, Vinci, M., additional, Perryman, L., additional, Box, G., additional, Jury, A., additional, Popov, S., additional, Ingram, W., additional, Eccles, S., additional, Robinson, S., additional, Emir, S., additional, Demir, H. A., additional, Bayram, C., additional, Cetindag, F., additional, Kabacam, G. B., additional, Fettah, A., additional, Li, J., additional, Jamin, Y., additional, Cummings, C., additional, Bamber, J., additional, Sinkus, R., additional, Nandhabalan, M., additional, Bjerke, L., additional, Burford, A., additional, von Bueren, A., additional, Baudis, M., additional, Clarke, P., additional, Collins, I., additional, Workman, P., additional, Olaciregui, N., additional, Mora, J., additional, Carcaboso, A., additional, Bullock, A., additional, Alonso, M., additional, de Torres, C., additional, Cruz, O., additional, Pencreach, E., additional, Moussalieh, F. M., additional, Guenot, D., additional, Namer, I., additional, Pollack, I., additional, Jakacki, R., additional, Butterfield, L., additional, Hamilton, R., additional, Panigrahy, A., additional, Potter, D., additional, Connelly, A., additional, Dibridge, S., additional, Whiteside, T., additional, Okada, H., additional, Ahsan, S., additional, Raabe, E., additional, Haffner, M., additional, Warren, K., additional, Quezado, M., additional, Ballester, L., additional, Eberhart, C., additional, Rodriguez, F., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Classen, C. F., additional, Hofmann, M., additional, Schmid, I., additional, Simon, T., additional, Maass, E., additional, Russo, A., additional, Fleischhack, G., additional, Becker, M., additional, Hauch, H., additional, Sander, A., additional, Grasso, C., additional, Berlow, N., additional, Liu, L., additional, Davis, L., additional, Huang, E., additional, Woo, P., additional, Tang, Y., additional, Ponnuswami, A., additional, Chen, S., additional, Huang, Y., additional, Hutt-Cabezas, M., additional, Dret, L., additional, Meltzer, P., additional, Mao, H., additional, Abraham, J., additional, Fouladi, M., additional, Svalina, M. N., additional, Wang, N., additional, Hulleman, E., additional, Li, X.-N., additional, Keller, C., additional, Spellman, P. T., additional, Pal, R., additional, Jansen, M. H. A., additional, Sewing, A. C. P., additional, Lagerweij, T., additional, Vuchts, D. J., additional, van Vuurden, D. G., additional, Caretti, V., additional, Wesseling, P., additional, Kaspers, G. J. L., additional, Cohen, K., additional, Pearl, M., additional, Kogiso, M., additional, Zhang, L., additional, Qi, L., additional, Lindsay, H., additional, Lin, F., additional, Berg, S., additional, Muscal, J., additional, Amayiri, N., additional, Tabori, U., additional, Campbel, B., additional, Bakry, D., additional, Aronson, M., additional, Durno, C., additional, Gallinger, S., additional, Malkin, D., additional, Qaddumi, I., additional, Musharbash, A., additional, Swaidan, M., additional, Al-Hussaini, M., additional, Shandilya, S., additional, McCully, C., additional, Murphy, R., additional, Akshintala, S., additional, Cole, D., additional, Macallister, R. P., additional, Cruz, R., additional, Widemann, B., additional, Salloum, R., additional, Smith, A., additional, Glaunert, M., additional, Ramkissoon, A., additional, Peterson, S., additional, Baker, S., additional, Chow, L., additional, Sandgren, J., additional, Pfeifer, S., additional, Popova, S., additional, Alafuzoff, I., additional, de Stahl, T. D., additional, Pietschmann, S., additional, Kerber, M. J., additional, Zwiener, I., additional, Henke, G., additional, Muller, K., additional, Sieow, N. Y.-F., additional, Hoe, R. H. M., additional, Tan, A. M., additional, Chan, M. Y., additional, Soh, S. Y., additional, Burrell, K., additional, Chornenkyy, Y., additional, Remke, M., additional, Golbourn, B., additional, Barzczyk, M., additional, Taylor, M., additional, Rutka, J., additional, Dirks, P., additional, Zadeh, G., additional, Agnihotri, S., additional, Hashizume, R., additional, Ihara, Y., additional, Andor, N., additional, Chen, X., additional, Lerner, R., additional, Huang, X., additional, Tom, M., additional, Solomon, D., additional, Mueller, S., additional, Petritsch, C., additional, Zhang, Z., additional, Gupta, N., additional, Waldman, T., additional, Dujua, A., additional, Co, J., additional, Hernandez, F., additional, Doromal, D., additional, Hegde, M., additional, Wakefield, A., additional, Brawley, V., additional, Grada, Z., additional, Byrd, T., additional, Chow, K., additional, Krebs, S., additional, Heslop, H., additional, Gottschalk, S., additional, Yvon, E., additional, Ahmed, N., additional, Cornilleau, G., additional, Paulsson, J., additional, Andreiuolo, F., additional, Guerrini-Rousseau, L., additional, Geoerger, B., additional, Vassal, G., additional, Ostman, A., additional, Parsons, D. W., additional, Trevino, L. R., additional, Gao, F., additional, Shen, X., additional, Hampton, O., additional, Kosigo, M., additional, Baxter, P. A., additional, Su, J. M., additional, Chintagumpala, M., additional, Dauser, R., additional, Adesina, A., additional, Plon, S. E., additional, Wheeler, D. A., additional, Lau, C. C., additional, Gielen, G., additional, Muehlen, A. z., additional, Kwiecien, R., additional, Wolff, J., additional, Lulla, R. R., additional, Laskowski, J., additional, Goldman, S., additional, Gopalakrishnan, V., additional, Fangusaro, J., additional, Kieran, M., additional, Fontebasso, A., additional, Papillon-Cavanagh, S., additional, Schwartzentruber, J., additional, Nikbakht, H., additional, Gerges, N., additional, Fiset, P.-O., additional, Bechet, D., additional, Faury, D., additional, De Jay, N., additional, Ramkissoon, L., additional, Corcoran, A., additional, Jones, D., additional, Sturm, D., additional, Johann, P., additional, Tomita, T., additional, Nagib, M., additional, Bendel, A., additional, Goumnerova, L., additional, Bowers, D. C., additional, Leonard, J. R., additional, Rubin, J. B., additional, Alden, T., additional, DiPatri, A., additional, Browd, S., additional, Leary, S., additional, Jallo, G., additional, Prados, M. D., additional, Banerjee, A., additional, Carret, A.-S., additional, Ellezam, B., additional, Crevier, L., additional, Klekner, A., additional, Bognar, L., additional, Hauser, P., additional, Garami, M., additional, Myseros, J., additional, Dong, Z., additional, Siegel, P. M., additional, Gump, W., additional, Ayyanar, K., additional, Ragheb, J., additional, Krieger, M., additional, Kiehna, E., additional, Robison, N., additional, Harter, D., additional, Gardner, S., additional, Handler, M., additional, Foreman, N., additional, Brahma, B., additional, MacDonald, T., additional, Malkin, H., additional, Chi, S., additional, Manley, P., additional, Bandopadhayay, P., additional, Greenspan, L., additional, Ligon, A., additional, Albrecht, S., additional, Ligon, K. L., additional, Majewski, J., additional, Jabado, N., additional, Cordero, F., additional, Halvorson, K., additional, Taylor, I., additional, Hutt, M., additional, Weingart, M., additional, Price, A., additional, Kantar, M., additional, Onen, S., additional, Kamer, S., additional, Turhan, T., additional, Kitis, O., additional, Ertan, Y., additional, Cetingul, N., additional, Anacak, Y., additional, Akalin, T., additional, Ersahin, Y., additional, Mason, G., additional, Ho, C., additional, Crozier, F., additional, Vezina, G., additional, Packer, R., additional, Hwang, E., additional, Gilheeney, S., additional, Millard, N., additional, DeBraganca, K., additional, Khakoo, Y., additional, Kramer, K., additional, Wolden, S., additional, Donzelli, M., additional, Fischer, C., additional, Petriccione, M., additional, Dunkel, I., additional, Afzal, S., additional, Fleming, A., additional, Larouche, V., additional, Zelcer, S., additional, Johnston, D. L., additional, Kostova, M., additional, Mpofu, C., additional, Decarie, J.-C., additional, Strother, D., additional, Lafay-Cousin, L., additional, Eisenstat, D., additional, Fryer, C., additional, Hukin, J., additional, Hsu, M., additional, Lasky, J., additional, Moore, T., additional, Liau, L., additional, Davidson, T., additional, Prins, R., additional, Hassal, T., additional, Baugh, J., additional, Kirkendall, J., additional, Doughman, R., additional, Leach, J., additional, Jones, B., additional, Miles, L., additional, Hargrave, D., additional, Jacques, T., additional, Savage, S., additional, Saunders, D., additional, Wallace, R., additional, Flutter, B., additional, Morgenestern, D., additional, Blanco, E., additional, Howe, K., additional, Lowdell, M., additional, Samuel, E., additional, Michalski, A., additional, Anderson, J., additional, Arakawa, Y., additional, Umeda, K., additional, Watanabe, K.-i., additional, Mizowaki, T., additional, Hiraoka, M., additional, Hiramatsu, H., additional, Adachi, S., additional, Kunieda, T., additional, Takagi, Y., additional, Miyamoto, S., additional, Venneti, S., additional, Santi, M., additional, Felicella, M. M., additional, Sullivan, L. M., additional, Dolgalev, I., additional, Martinez, D., additional, Perry, A., additional, Lewis, P. W., additional, Allis, D. C., additional, Thompson, C. B., additional, and Judkins, A. R., additional
- Published
- 2014
- Full Text
- View/download PDF
20. Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma
- Author
-
Yildiz, I., primary, Sen, F., additional, Kilic, L., additional, Ekenel, M., additional, Ordu, C., additional, Kilicaslan, I., additional, Darendeliler, E., additional, Tunc, H.M., additional, Varol, U., additional, Bavbek, S., additional, and Basaran, M., additional
- Published
- 2013
- Full Text
- View/download PDF
21. IMMUNOTHERAPY/BIOLOGICAL THERAPIES
- Author
-
Campian, J., primary, Gladstone, D., additional, Ambady, P., additional, Ye, X., additional, King, K., additional, Borrello, I., additional, Petrik, S., additional, Golightly, M., additional, Holdhoff, M., additional, Grossman, S., additional, Bhardwaj, R., additional, Chakravadhanula, M., additional, Ozols, V., additional, Georges, J., additional, Carlson, E., additional, Hampton, C., additional, Decker, W., additional, Chiba, Y., additional, Hashimoto, N., additional, Kagawa, N., additional, Hirayama, R., additional, Tsuboi, A., additional, Oji, Y., additional, Oka, Y., additional, Sugiyama, H., additional, Yoshimine, T., additional, Choi, B., additional, Gedeon, P., additional, Herndon, J., additional, Sanchez-Perez, L., additional, Mitchell, D., additional, Bigner, D., additional, Sampson, J., additional, Choi, Y. A., additional, Pandya, H., additional, Gibo, D. M., additional, Debinski, W., additional, Cloughesy, T. F., additional, Liau, L. M., additional, Chiocca, E. A., additional, Jolly, D. J., additional, Robbins, J. M., additional, Ostertag, D., additional, Ibanez, C. E., additional, Gruber, H. E., additional, Kasahara, N., additional, Vogelbaum, M. A., additional, Kesari, S., additional, Mikkelsen, T., additional, Kalkanis, S., additional, Landolfi, J., additional, Bloomfield, S., additional, Foltz, G., additional, Pertschuk, D., additional, Everson, R., additional, Jin, R., additional, Safaee, M., additional, Lisiero, D., additional, Odesa, S., additional, Liau, L., additional, Prins, R., additional, Gholamin, S., additional, Mitra, S. S., additional, Richard, C. E., additional, Achrol, A., additional, Kahn, S. A., additional, Volkmer, A. K., additional, Volkmer, J. P., additional, Willingham, S., additional, Kong, D., additional, Shin, J. J., additional, Monje-Deisseroth, M., additional, Cho, Y.-J., additional, Weissman, I., additional, Cheshier, S. H., additional, Kanemura, Y., additional, Sumida, M., additional, Yoshioka, E., additional, Yamamoto, A., additional, Kanematsu, D., additional, Takada, A., additional, Nonaka, M., additional, Nakajima, S., additional, Goto, S., additional, Kamigaki, T., additional, Takahara, M., additional, Maekawa, R., additional, Shofuda, T., additional, Moriuchi, S., additional, Yamasaki, M., additional, Kebudi, R., additional, Cakir, F. B., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Darendeliler, E., additional, Lin, Y., additional, Wang, Y., additional, Qiu, X., additional, Jiang, T., additional, Zhang, G., additional, Wang, J., additional, Okada, H., additional, Butterfield, L., additional, Hamilton, R., additional, Drappatz, J., additional, Engh, J., additional, Amankulor, N., additional, Lively, M., additional, Chan, M., additional, Salazar, A., additional, Potter, D., additional, Shaw, E., additional, Lieberman, F., additional, Choi, Y., additional, Park, J., additional, Phuphanich, S., additional, Wheeler, C., additional, Rudnick, J., additional, Hu, J., additional, Mazer, M., additional, Wang, H., additional, Nuno, M., additional, Guevarra, A., additional, Sanchez, C., additional, Fan, X., additional, Ji, J., additional, Chu, R., additional, Bender, J., additional, Hawkins, E., additional, Black, K., additional, Yu, J., additional, Reap, E., additional, Archer, G., additional, Norberg, P., additional, Schmittling, R., additional, Nair, S., additional, Cui, X., additional, Snyder, D., additional, Chandramohan, V., additional, Kuan, C.-T., additional, Yan, H., additional, Reardon, D., additional, Li, G., additional, Recht, L., additional, Fink, K., additional, Nabors, L., additional, Tran, D., additional, Desjardins, A., additional, Chandramouli, N., additional, Duic, J. P., additional, Groves, M., additional, Clarke, A., additional, Hawthorne, T., additional, Green, J., additional, Yellin, M., additional, Rigakos, G., additional, Spyri, O., additional, Nomikos, P., additional, Stavridi, F., additional, Grossi, I., additional, Theodorakopoulou, I., additional, Assi, A., additional, Kouvatseas, G., additional, Papadopoulou, E., additional, Nasioulas, G., additional, Labropoulos, S., additional, Razis, E., additional, Ravi, A., additional, Tang, D. N., additional, Sharma, P., additional, Sengupta, S., additional, Sampath, P., additional, Soto, H., additional, Erickson, K., additional, Malone, C., additional, Hickey, M., additional, Ha, E., additional, Young, E., additional, Ellingson, B., additional, Kruse, C., additional, Sul, J., additional, Hilf, N., additional, Kutscher, S., additional, Schoor, O., additional, Lindner, J., additional, Reinhardt, C., additional, Kreisl, T., additional, Iwamoto, F., additional, Fine, H., additional, Singh-Jasuja, H., additional, Teijeira, L., additional, Gil-Arnaiz, I., additional, Hernandez-Marin, B., additional, Martinez-Aguillo, M., additional, Sanchez, S. d. l. C., additional, Viudez, A., additional, Hernandez-Garcia, I., additional, Lecumberri, M. J., additional, Grandez, R., additional, de Lascoiti, A. F., additional, Garcia, R. V., additional, Thomas, A., additional, Fisher, J., additional, Baron, U., additional, Olek, S., additional, Rhodes, H., additional, Gui, J., additional, Hampton, T., additional, Tafe, L., additional, Tsongalis, G., additional, Lefferts, J., additional, Wishart, H., additional, Kleen, J., additional, Miller, M., additional, Ernstoff, M., additional, Fadul, C., additional, Vlahovic, G., additional, Peters, K., additional, Ranjan, T., additional, Friedman, A., additional, Friedman, H., additional, Lally-Goss, D., additional, Wainwright, D., additional, Dey, M., additional, Chang, A., additional, Cheng, Y., additional, Han, Y., additional, Lesniak, M., additional, Weller, M., additional, Kaulich, K., additional, Hentschel, B., additional, Felsberg, J., additional, Gramatzki, D., additional, Pietsch, T., additional, Simon, M., additional, Westphal, M., additional, Schackert, G., additional, Tonn, J. C., additional, Loeffler, M., additional, Reifenberger, G., additional, Xu, M., additional, and Patil, C., additional
- Published
- 2013
- Full Text
- View/download PDF
22. Non-resective management of pineoblastoma
- Author
-
Cicek Bayindir, Darendeliler E, Ayan I, Murat Imer, and Orhan Barlas
- Subjects
Adult ,Male ,medicine.medical_specialty ,Stereotactic biopsy ,Adolescent ,medicine.medical_treatment ,Biopsy ,Pineal Gland ,Ventriculostomy ,Central nervous system disease ,Cerebrospinal fluid diversion ,medicine ,Humans ,Derivation ,Child ,Pineoblastoma ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Magnetic resonance imaging ,General Medicine ,medicine.disease ,Magnetic Resonance Imaging ,Cerebrospinal Fluid Shunts ,Surgery ,Radiation therapy ,Treatment Outcome ,Child, Preschool ,Female ,Neurology (clinical) ,Neoplasm Recurrence, Local ,business ,Tomography, X-Ray Computed ,Pinealoma ,Follow-Up Studies - Abstract
The results of a non-resective treatment approach for pineoblastoma comprising stereotactic biopsy, cerebrospinal fluid diversion, and fractionated radiotherapy in six patients over a period of six years are presented. There were three male and three female patients, with a median age at diagnosis of 20 years. Magnetic resonance imaging of the spine, ventricular cerebrospinal fluid cytology, and tumour markers in cerebrospinal fluid were negative. Tumour response to initial radiotherapy was complete in three patients and partial in three patients. Recurrences were treated with interstitial irradiation with iodine-125 seeds in four instances, repeat radiotherapy when time elapsed was more than five years in one instance, with surgical resection in two instances, and chemotherapy in two instances. The diagnostic and therapeutic effectiveness of this management strategy is assessed. There were no complications related to surgical procedures. The median follow-up time was 48 months (range 14-70 months). Five patients were alive at 14, 45, 51, 57, and 70 months of follow-up. One patient died of disease at 28 months following diagnosis. The overall survival rate was 80 % +/- 17.89 % at 28 months. The results of this study suggest that this non-resective treatment approach is acceptable as an initial treatment alternative to radical surgical resection of pineoblastomas.
- Published
- 2000
23. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
- Author
-
Zaghloul, M., primary, Ahmed, S., additional, Eldebaway, E., additional, Mousa, A., additional, Amin, A., additional, Elkhateeb, N., additional, Sabry, M., additional, Ogiwara, H., additional, Morota, N., additional, Sufit, A., additional, Donson, A., additional, Birks, D., additional, Patel, P., additional, Foreman, N., additional, Handler, M., additional, Massimino, M., additional, Biassoni, V., additional, Gandola, L., additional, Schiavello, E., additional, Pecori, E., additional, Potepan, P., additional, Bach, F., additional, Janssens, G. O., additional, Jansen, M. H., additional, Lauwers, S. J., additional, Nowak, P. J., additional, Oldenburger, F. R., additional, Bouffet, E., additional, Saran, F., additional, van Ulzen, K. K., additional, van Lindert, E. J., additional, Schieving, J. H., additional, Boterberg, T., additional, Kaspers, G. J., additional, Span, P. N., additional, Kaanders, J. H., additional, Gidding, C. E., additional, Hargrave, D., additional, Bailey, S., additional, Howman, A., additional, Pizer, B., additional, Harris, D., additional, Jones, D., additional, Kearns, P., additional, Picton, S., additional, Wheatley, K., additional, Gibson, M., additional, Glaser, A., additional, Connolly, D., additional, Kawamura, A., additional, Nagashima, T., additional, Yamamoto, K., additional, Sakata, J., additional, Lober, R., additional, Freret, M., additional, Fisher, P., additional, Edwards, M., additional, Yeom, K., additional, Monje, M., additional, Jansen, M., additional, Aliaga, E. S., additional, Van Der Hoeven, E., additional, Van Vuurden, D., additional, Heymans, M., additional, Gidding, C., additional, De Bont, E., additional, Reddingius, R., additional, Peeters-Scholte, C., additional, van Meeteren, A. S., additional, Gooskens, R., additional, Granzen, B., additional, Paardekoper, G., additional, Janssens, G., additional, Noske, D., additional, Barkhof, F., additional, Vandertop, W. P., additional, Kaspers, G., additional, Saratsis, A., additional, Yadavilli, S., additional, Nazarian, J., additional, Mitra, S., additional, Mallick, S., additional, Kim, J., additional, Beachy, P., additional, Nobre, L., additional, Vasconcelos, F., additional, Lima, F., additional, Mattos, D., additional, Kuiven, N., additional, Lima, G., additional, Silveira, J., additional, Sevilha, M., additional, Lima, M. A., additional, Ferman, S., additional, Leblond, P., additional, Lansiaux, A., additional, Rialland, X., additional, Gentet, J.-C., additional, Geoerger, B., additional, Frappaz, D., additional, Aerts, I., additional, Bernier-Chastagner, V., additional, Shah, R., additional, Zaky, W., additional, Grimm, J., additional, Bluml, S., additional, Wong, K., additional, Dhall, G., additional, Caretti, V., additional, Schellen, P., additional, Lagerweij, T., additional, Bugiani, M., additional, Navis, A., additional, Wesseling, P., additional, Noske, D. P., additional, Wurdinger, T., additional, Lee, H., additional, Ziegler, D., additional, Schroeder, K., additional, Huang, E., additional, Berlow, N., additional, Patel, R., additional, Becher, O., additional, Taylor, I., additional, Mao, X.-g., additional, Hutt, M., additional, Weingart, M., additional, Kahlert, U., additional, Maciacyk, J., additional, Nikkhah, G., additional, Eberhart, C., additional, Raabe, E., additional, Barton, K., additional, Misuraca, K., additional, Zhou, Z., additional, Rotman, L., additional, Ho, S., additional, Souweidane, M., additional, Lim, K. J., additional, Warren, K., additional, Chang, H., additional, Lightner, D., additional, Haque, S., additional, Khakoo, Y., additional, Dunkel, I., additional, Gilheeney, S., additional, Kramer, K., additional, Lyden, D., additional, Wolden, S., additional, Greenfield, J., additional, De Braganca, K., additional, Ting-Rong, H., additional, Muh-Li, L., additional, Kai-Ping, C., additional, Tai-Tong, W., additional, Hsin-Hung, C., additional, Kebudi, R., additional, Cakir, F. B., additional, Agaoglu, F. Y., additional, Gorgun, O., additional, Dizdar, Y., additional, Ayan, I., additional, Darendeliler, E., additional, Zapotocky, M., additional, Churackova, M., additional, Malinova, B., additional, Kodet, R., additional, Kyncl, M., additional, Tichy, M., additional, Stary, J., additional, Sumerauer, D., additional, Minturn, J., additional, Shu, H.-K., additional, Fisher, M., additional, Patti, R., additional, Janss, A., additional, Allen, J., additional, Phillips, P., additional, Belasco, J., additional, Taylor, K., additional, Baudis, M., additional, von Beuren, A., additional, Fouladi, M., additional, and Jones, C., additional
- Published
- 2012
- Full Text
- View/download PDF
24. Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
- Author
-
Yildiz, I., primary, Sen, F., additional, Basaran, M., additional, Ekenel, M., additional, Agaoglu, F., additional, Darendeliler, E., additional, Tunc, H. M., additional, Ozcan, F., additional, and Bavbek, S., additional
- Published
- 2011
- Full Text
- View/download PDF
25. Second malignant tumors in childhood cancer survivors.
- Author
-
Kebudi, R., primary, Ayan, I., additional, Gorgun, O., additional, Agaoglu, F. Y., additional, Ozdemir, G. N., additional, Dizdar, Y., additional, Zulfikar, B., additional, and Darendeliler, E., additional
- Published
- 2011
- Full Text
- View/download PDF
26. Childhood osteosarcoma: Evaluation of 94 cases. A single institution study
- Author
-
Ayan, I., primary, Kebudi, R., additional, Ozger, H., additional, Yaman Agaoglu, F., additional, Gorgun, O., additional, Bilgic, B., additional, Eralp, L., additional, Dizdar, Y., additional, and Darendeliler, E., additional
- Published
- 2009
- Full Text
- View/download PDF
27. Multimodality treatment on long-term outcome of intracranial germ cell tumors in children: A single institution study
- Author
-
Kebudi, R., primary, Darendeliler, E., additional, Ayan, I., additional, Gorgun, O., additional, Yaman Agaoglu, F., additional, Dizdar, Y., additional, Darendeliler, F., additional, and Emiroglu, H., additional
- Published
- 2009
- Full Text
- View/download PDF
28. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: Review of 30 cases
- Author
-
Tas, F., primary, Fayda, M., additional, Aksu, G., additional, Agaoglu, F. Y., additional, Karadeniz, A., additional, Darendeliler, E., additional, Altun, M., additional, and Uygun, K., additional
- Published
- 2007
- Full Text
- View/download PDF
29. Optic pathway gliomas in children: A single institution study
- Author
-
Kebudi, R., primary, Ayrancı, O., additional, Tuncer, S., additional, Ayan, I., additional, Peksayar, G., additional, Gorgun, O., additional, and Darendeliler, E., additional
- Published
- 2007
- Full Text
- View/download PDF
30. Non-Resective Management of Pineoblastoma
- Author
-
Barlas, O, primary, Bayındır, Ç, additional, İmer, M, additional, Ayan, İ, additional, and Darendeliler, E, additional
- Published
- 2000
- Full Text
- View/download PDF
31. Prognostic factors in primary gastric non Hodgkin's lymphoma
- Author
-
Basaran, M., primary, Bavbek, S.E., additional, Alici, S., additional, Uygun, K., additional, Dogan, O., additional, Agan, M., additional, Darendeliler, E., additional, and Onat, H., additional
- Published
- 1999
- Full Text
- View/download PDF
32. Cyclophosphamide, vincristine, epirubicin and prednisolone (ceop-100) in aggressive Non Hodgkin's lymphoma (ANHL)
- Author
-
Bavbek, S.E., primary, Basaran, M., additional, Uygun, K., additional, Alici, S., additional, Darendeliler, E., additional, and Onat, H., additional
- Published
- 1999
- Full Text
- View/download PDF
33. Survival and prognostic factors in patients with Hodgkin's disease
- Author
-
Eralp, Y., primary, Bavbek, S., additional, Basaran, M., additional, Uygun, K., additional, Kaytan, E., additional, Çamlica, H., additional, Darendeliler, E., additional, and Onat, H., additional
- Published
- 1999
- Full Text
- View/download PDF
34. Prolonged survival with complete resection of lung metastases
- Author
-
İnanç, S.E., primary, Onat, H., additional, Darendeliler, E., additional, Çamlica, H., additional, and Kalayci, G., additional
- Published
- 1997
- Full Text
- View/download PDF
35. Immunologic changes in children with bone and soft tissue sarcomas
- Author
-
Kebudi, R, primary, Ayan, I, additional, Darendeliler, E, additional, Aǧaoǧlu, L, additional, Yaǧci, T, additional, Pişkin, S, additional, and Bilge, N, additional
- Published
- 1993
- Full Text
- View/download PDF
36. Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: comparison of femur doses for four treatment techniques.
- Author
-
Karaçetin D, Çakir A, Agaoglu F, Camlica H, Ergen A, Dizdar Y, and Darendeliler E
- Abstract
Purpose: Conformal radiotherapy of the prostate is an increasingly common technique in the treatment of prostate cancer. When using 3D conformal radiotherapy (CFRT) methods, it is desirable to protect the vital structures such as bladder, rectum, and femur. In this study, our aim was to compare the femur head doses resulting from co-planar beam arrangements in four-field (4F), five-field (5F), six-field (6F) and seven-field (7F) treatment plans, in a dose-escalated CFRT schedule. Materials and Methods: From January 2005 to December 2006, at Istanbul University Medical Faculty of Radiation Oncology Clinic, a total of 22 patients with carcinoma of the prostate had been scanned using computed tomography (CT) (0.50 mm) in the supine position. During the CT scanning which used the Sim Pro (CMDDSUSA) programme, planned target volume (PTV), clinical target volume (CTV), and dose volumes received by the bladder, rectum and femur heads were recorded and doseDSvolume histogram (DVH) were created. The dose volume relating to prostate and seminal vesicles was termed CTV 1, and the dose volume relating to prostate alone was termed CTV 2. During the formation of PTV, into CTV 1, from the anterior-superior-inferior 8 mm, and from posterior 5 mm tolerance were taken into account. After volume determination is calculated using XiO (CMS-USA) 3D treatment planning computer, each patient 4F (45° - 25%, 135° - 25%, 225° - 25%, 315° - 25%), 5F (0° - 20%, 45° - 20%, 90° - 20%, 270° - 20%, 315° - 20%), 6F (45° - 20%, 90° - 10%, 135° 20%, 315° - 20%, 270° - 10%, 225° - 20%) and 7F (0° - 4%, 45° - 12.9%, 90° - 22.2%, 135° - 12.9%, 315° - 12.9%, 270°- 22.2%, 225° - 12.9%) was entered; 70 - 76 Gy was calculated to be given to prostate lodge. With the use of Siemes Oncor, 18 MV photons CFRT was applied. In DVH analysis, following were observed: V50, minimum and maximum doses for head of left femur and right femur total doses. Results: Our statistical evaluation was made using SPSS software, and we found femur doses following; 4F V50 1030 cGy (minimum 58, maximum 1390), 5F V50 2425 cGy (minimum 540, maximum 3631), 6F V50 1769 cGy (minimum 1234, maximum 3912) and 7F V50 3230 cGy (minimum 2150, maximum 4137). In comparing different techniques, the greatest rectal sparing was achieved by the 5F plan. (Rectal: 5F V%25 = 59.90 ± 6.8 Gy, 4F V%25 = 62.30 ± 10.3 Gy, 6F V%25 = 69.36 ± 5.7 Gy, 7F V%25 = 61.32 ± 7.3 Gy). The greatest femoral head sparing was achieved by the 4F techniques. When paired samples t-test was made, we found considerable lower femur doses for 4F techniques (p = 0.05). Conclusion: We concluded that, during radiotherapy to treat carcinoma of the prostate, the dose received by the rectum is the most important factor to consider, given the potential for late toxicity in this organ. However, while using lateral fields (90-270°) so as to protect the rectum, the doses received by the femur heads were observed to be higher. Especially in older patients, the critical doses of 52 Gy for TD5/5 and 65 Gy for TD 50/5 were observed to be not reached late toxicity for 4F, 5F, 6F and 7F. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
37. A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer
- Author
-
Sarihan, S., Darendeliler, E., Kizir, A., Tuncel, N., Oral, E. N., Karadeniz, A., and Bilge, N.
- Published
- 1998
- Full Text
- View/download PDF
38. Microscopic Local Leptomeningeal Invasion at Diagnosis of Medulloblastoma
- Author
-
Ayan, I., Kebudi, R., Bayindir, C., and Darendeliler, E.
- Published
- 1997
- Full Text
- View/download PDF
39. Primary uterine lymphoma: case report and literature review.
- Author
-
Agaoglu FY, Fayda M, Dizdar Y, Basaran M, Yazar A, and Darendeliler E
- Published
- 2005
- Full Text
- View/download PDF
40. Clinical characteristics, late effects and outcomes in pineoblastomas in children: a single center experience.
- Author
-
Görgün Ö, Koç B, Kebudi R, Wolff JE, Kebudi A, and Darendeliler E
- Subjects
- Child, Humans, Retrospective Studies, Treatment Outcome, Brain Neoplasms diagnosis, Brain Neoplasms therapy, Pineal Gland, Pinealoma diagnosis, Pinealoma therapy
- Abstract
Background: Pineoblastomas (PB) are rare tumors of the central nervous system and are more common in children. There is no consensus about standard of care. The objective of this study is to analyze the outcome of children with PB., Methods: Six patients with PB who were diagnosed between 1990-2012 were evaluated retrospectively. Demographics, age of diagnosis, first complaint, tumor region, diagnosis type, seeding metastasis to the spinal axis or cerebrospinal fluid (CSF), treatment and survival of these patients were recorded., Results: Three patients had subtotal resection and all patients received chemotherapy and craniospinal irradiation (CSI) after diagnosis. Median follow-up after treatment was 5.5 (range:1-19) years. Two patients are alive with no evidence of disease for 7.5 and 10 years, one of whom was diagnosed with papillary thyroid carcinoma 9.5 years after treatment. One of the patients who died had lived for 19 years after diagnosis., Conclusions: Pineoblastomas are rare but very aggressive tumors; more effective treatment strategies are needed. Survivors should be followed up for late effects such as second malignancies and endocrine deficiencies.
- Published
- 2021
- Full Text
- View/download PDF
41. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.
- Author
-
Ozyigit G, Onal C, Igdem S, Alicikus ZA, Iribas A, Akin M, Yalman D, Cetin I, Aksu MG, Atalar B, Dincbas F, Hurmuz P, Guler OC, Aydin B, Sert F, Yildirim C, Gorken IB, Agaoglu FY, Korcum AF, Yuce D, Ozkok S, Darendeliler E, and Akyol F
- Subjects
- Adult, Aged, Aged, 80 and over, Androgen Antagonists therapeutic use, Combined Modality Therapy, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Radiotherapy Dosage, Survival Rate, Treatment Outcome, Turkey, Prostatic Neoplasms radiotherapy
- Abstract
Purpose: To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8-10 disease treated with external beam radiotherapy (EBRT) + androgen deprivation therapy (ADT) in the modern era., Methods: Institutional databases of biopsy proven 641 patients with GS 8-10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. The inclusion criteria were, T1-T3N0M0 disease according to AJCC (American Joint Committee on Cancer) 2010 Staging System, no prior diagnosis of malignancy, at least 70 Gy total irradiation dose to prostate ± seminal vesicles delivered with either three-dimensional conformal RT or intensity-modulated RT and patients receiving ADT., Results: The median follow-up time was 5.9 years (range 0.4-18.2 years); 5‑year overall survival (OS), biochemical relapse-free survival (BRFS) and distant metastases-free survival (DMFS) rates were 88%, 78%, and 79%, respectively. Higher RT doses (≥78 Gy) and longer ADT duration (≥2 years) were significant predictors for improved DMFS, whereas advanced stage was a negative prognosticator for DMFS in patients with GS 9-10., Conclusions: Our results validated the fact that oncologic outcomes after radical EBRT significantly differ in men with GS 8 versus those with GS 9-10 prostate cancer. We found that EBRT dose was important predictive factor regardless of ADT period. Patients receiving 'non-optimal treatment' (RT doses <78 Gy and ADT period <2 years) had the worst treatment outcomes.
- Published
- 2019
- Full Text
- View/download PDF
42. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
- Author
-
Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, and Çakır FB
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols adverse effects, Child, Child, Preschool, Female, Humans, Infant, Irinotecan administration & dosage, Male, Remission Induction, Retreatment, Survival Rate, Temozolomide administration & dosage, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bone Neoplasms therapy, Kidney Neoplasms therapy, Neoplasm Recurrence, Local drug therapy, Neuroblastoma therapy, Osteosarcoma therapy, Rhabdomyosarcoma therapy, Sarcoma, Ewing therapy, Wilms Tumor therapy
- Abstract
Background: Although the survival of pediatric cancer has increased dramatically in the last decades, the survival of refractory, relapsed, and metastatic cases is still dismal. The combination of irinotecan and temozolomide has shown activity against refractory/relapsed pediatric solid tumors., Method: Thirty-four children with refractory/relapsed solid tumors who had previously been heavily pretreated and who were given vincristine, irinotecan, and temozolomide as third- or further line chemotherapy during 2004-2015 were evaluated., Results: Patients were diagnosed with Ewing sarcoma (n = 15), rhabdomyosarcoma (n = 8), neuroblastoma (n = 8), osteosarcoma (n = 2), and Wilms' tumor (n = 1). Thirty patients presented with disease progression on therapy and the other four presented with relapsing. A total of 141 cycles were administered. Radiotherapy was used in 17 patients and surgery in 4 as local therapy. Among all patients, 6 had complete response, 3 had partial response, 14 had stable disease, and 11 had progressive disease. The objective response was 26.4% (complete response + partial response) and median survival duration was six months. The first and second year overall survival rates were 22.3% and 16.8%. The objective response in Ewing sarcoma patients was 40%. Diarrhea was the most common toxicity and 14 (10%) courses were associated with grade 3-4 diarrhea., Conclusions: In heavily pretreated patients with refractory/relapsed solid tumors, the vincristine, irinotecan, and temozolomide regimen seemed promising in Ewing sarcoma patients and was well tolerated.
- Published
- 2019
- Full Text
- View/download PDF
43. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
- Author
-
Kebudi R, Cakir FB, Bay SB, Gorgun O, Altınok P, Iribas A, Agaoglu FY, and Darendeliler E
- Subjects
- Adolescent, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents administration & dosage, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carboplatin administration & dosage, Child, Child, Preschool, Combined Modality Therapy, Female, Humans, Male, Progression-Free Survival, Retrospective Studies, Survival Analysis, Temozolomide administration & dosage, Vinorelbine administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Stem Neoplasms drug therapy, Glioma drug therapy
- Abstract
Purpose: Nimotuzumab is an IgG1 antibody that targets epidermal growth factor receptor (EGFR). Overexpression of EGFR is detected in some pediatric brain tumors including diffuse intrinsic pontine gliomas (DIPG)s., Methods: Since May 2010, nimotuzumab, combined with carboplatin or vinorelbine or Temozolomide (TMZ), was administered during progressive disease (PD) after the use of the institutional protocol consisting of radiotherapy (RT) + TMZ and adjuvant TMZ. After May 2012, children with newly diagnosed disease received TMZ during RT, and nimotuzumab and TMZ after RT. Nimotuzumab was given as 150 mg/m
2 /dose once a week for 12 weeks, and then every other week with TMZ until PD. PD patients were switched to nimotuzumab + vinorelbine combination until death., Results: Nimotuzumab was used in 24 children with DIPG (seven in the PD group, 17 in the newly diagnosed patient group). In the PD group, median survival time was 12 months (7-42 months); 1-year and 2-year overall survival (OS) rates were 42.9 ± 18% and 14.3 ± 13%, respectively. The median survival in this group, after the initiation of nimotuzumab was 6 months (3-8 months). In the newly diagnosed patient group, median survival time was 11 months (3-35 months) and median progression free survival was 4 months (1-21 months). The 1-year OS in this group was 35.3 ± 11% and 2 year OS was 11.8 ± 7%. Nimotuzumab ± chemotherapy was well tolerated with no major adverse effect., Conclusion: Nimotuzumab-containing regimens are feasible and tolerable; it might be that some patients either with newly diagnosed DIPG or with progressive disease may benefit modestly from nimotuzumab-containing combinations.- Published
- 2019
- Full Text
- View/download PDF
44. RE: Osteosarcoma of the rib: a rare presentation.
- Author
-
Bay SB, Kebudi R, İribaş A, Görgün Ö, Ağaoğlu F, Gün F, Çelik A, and Darendeliler E
- Published
- 2018
- Full Text
- View/download PDF
45. Primary Rhabdomyosarcoma of the Breast: Imaging Findings and Literature Review.
- Author
-
Bayramoglu Z, Kebudi R, Yilmaz R, Buyukkapu Bay S, Kebudi A, Karanlik H, Iribas A, Darendeliler E, Onder S, Bilgic B, and Adaletli I
- Abstract
Background: Primary breast rhabdomyosarcoma (RMS) can occur in children. There is a lack of knowledge regarding radiologic findings and added diffusion-weighted magnetic resonance imaging (MRI) features of RMS in the literature., Case Report: A 12-year-old girl was diagnosed with primary alveolar RMS of the breast. Gray scale ultrasound revealed posterior acoustic enhancement behind a well-circumscribed, multilobulated hypoechoic mass. Doppler ultrasound revealed increased peripheral and central vascularity. Hypointense septations on T2-weighted image exhibiting more enhancement than the stroma on late gadolinium-enhanced images were striking within a hyperintense mass. A hyperintense hemorrhagic focus on T1-weighted image was present in the absence of any necrosis. Avid enhancement on early postcontrast images proceeding from the periphery to the center was depicted., Conclusion: A rapidly enlarging mass with an echogenic peripheral rim together with posterior acoustic enhancement on gray scale ultrasound, intense vascularity on Doppler ultrasound, axillary lymphadenopathy, and satellite nodules on MRI should raise suspicion. Enhancing central and peripheral septations are suggestive of RMS. Dynamic contrast-enhanced MRI in suspected cases can provide valuable data in the differential diagnosis.
- Published
- 2018
- Full Text
- View/download PDF
46. Absolute dose verification of static intensity modulated radiation therapy (IMRT) with ion chambers of various volumes and TLD detectors.
- Author
-
Acun-Bucht H, Tuncay E, Darendeliler E, and Kemikler G
- Abstract
Aim: This study aims at examining absolute dose verification of step-and-shoot intensity modulated radiation treatment (IMRT) of prostate and brain patients by use of ion chambers of two different volumes and thermoluminescent detectors (TLD)., Background: The volume of the ion chamber (IC) is very important for absolute dose verification of IMRT plans since the IC has a volume average effect. With TLD detectors absolute dose verification can be done measuring the dose of multiple points simultaneously., Materials and Methods: Ion chambers FC65-P of volume 0.65 cc and semiflex of volume 0.125 cc as well as TLDs were used to measure the central axis absolute dose of IMRT quality assurance (QA) plans. The results were compared with doses calculated by a treatment planning system (TPS). The absolute doses of off axis points located 2 cm and 4 cm away from the isocenter were measured with TLDs., Results: The measurements of the 0.125 cc ion chamber were found to be closer to TPS calculations compared to the 0.65 cc ion chamber, for both patient groups. For both groups the root mean square (RMS) differences between doses of the TPS and the TLD detectors are within 3.0% for the central axis and points 2 cm away from the isocenter of each axis. Larger deviations were found at the field edges, which have steep dose gradient., Conclusions: The 0.125 cc ion chamber measures the absolute dose of the isocenter more accurately compared to the 0.65 cc chamber. TLDs have good accuracy (within 3.0%) for absolute dose measurements of in-field points.
- Published
- 2018
- Full Text
- View/download PDF
47. Osteosarcoma of the rib: A rare presentation.
- Author
-
Bay SB, Kebudi R, İribaş A, Görgün Ö, Ağaoğlu F, Gün F, Çelik A, and Darendeliler E
- Abstract
In children and adolescents with chest pain and dyspnea, pneumonia, pleural effusion, and empyema are the frequent causes in the differential diagnosis. Malignant tumors of the chest wall are rare and most originate from the ribs. In children, the most frequent malignant tumor of the rib is Ewing's sarcoma. Osteosarcomas of the rib are very rare. Osteosarcoma has a predilection for rapidly growing long bones including the femur, tibia and humerus in adolescents. In this paper, we present an adolescent girl who presented with chest pain and dyspnea with osteosarcoma that originated from the rib and extended to the right hemithorax., Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors.
- Published
- 2018
- Full Text
- View/download PDF
48. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
- Author
-
Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, and Turkmen C
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Middle Aged, Neoplasm Grading, Prostatic Neoplasms blood, Recurrence, Antigens, Surface metabolism, Gallium Radioisotopes, Glutamate Carboxypeptidase II metabolism, Positron Emission Tomography Computed Tomography, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms pathology
- Abstract
Aim: To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga
68 -PSMA PET/CT in patients with recurrent PCa., Methods: A total of 109 consecutive patients (median age 71 years; range 48-89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented., Results: In 91(83.4%) patients at least one lesion characteristic for PCa was detected by68 Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2-640) ng/ml.There was a significant difference between68 Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative68 Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative68 Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911-0.993)., Conclusions:68 Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and68 Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive68 Ga-PSMA PET/CT results.- Published
- 2017
- Full Text
- View/download PDF
49. PCA3 Silencing Sensitizes Prostate Cancer Cells to Enzalutamide-mediated Androgen Receptor Blockade.
- Author
-
Özgür E, Celik AI, Darendeliler E, and Gezer U
- Subjects
- Benzamides, Cell Line, Tumor, Cell Proliferation genetics, Cell Survival genetics, Gene Expression genetics, Gene Silencing physiology, Humans, Male, Nitriles, Phenylthiohydantoin pharmacology, Prostate metabolism, Prostate-Specific Antigen genetics, Prostatic Neoplasms, Castration-Resistant genetics, Prostatic Neoplasms, Castration-Resistant metabolism, Androgen Receptor Antagonists pharmacology, Antigens, Neoplasm genetics, Phenylthiohydantoin analogs & derivatives, Prostatic Neoplasms, Castration-Resistant drug therapy, Receptors, Androgen genetics
- Abstract
Background/aim: Prostate cancer (PCa) is an androgen-dependent disease. Novel anti-androgens (i.e. enzalutamide) have recently been developed for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Evidence is accumulating that prostate cancer antigen 3 (PCA3) is involved in androgen receptor (AR) signaling. Here, in combination with enzalutamide-mediated AR blockade, we investigated the effect of PCA3 targeting on the viability of PCa cells., Materials and Methods: In hormone-sensitive LNCaP cells, AR-overexpressing LNCaP-AR
+ cells and VCaP cells (representing CRPC), PCA3 was silenced using siRNA oligonucleotides. Gene expression and cell viability was assessed in PCA3-silenced and/or AR-blocked cells., Results: PCA3 targeting reduced the expression of AR-related genes (i.e. prostate-specific antigen (PSA) and prostate-specific transcript 1 (non-protein coding) (PCGEM1)) and potentiated the effect of enzalutamide. Proliferation of PCa cells was suppressed upon PCA3 silencing with a greater effect in LNCaP-AR+ cells. Furthermore, PCA3 silencing sensitized PCa cells to enzalutamide-induced loss of cell growth., Conclusion: PCA3, as a therapeutic target in PCa, might be used to potentiate AR antagonists., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
50. Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience.
- Author
-
Kılıç L, Ekenel M, Karabulut S, Ağaoğlu F, and Darendeliler E
- Abstract
Aim of the Study: Patients with large and high-grade extremity soft-tissue sarcoma are at significant risk for distant metastasis and sarcoma-related death. There is no randomized trial comparing chemoradiotherapy to radiotherapy in the neoadjuvant setting for high risk extremity soft-tissue sarcoma. The aim of this study is to evaluate the outcomes of patients treated with two different modalities (neoadjuvant sequential chemoradiotherapy vs. radiotherapy alone) in a single center., Material and Methods: Data of 67 patients were analyzed retrospectively. Thirty-four patients received neoadjuvant sequential chemoradiotherapy (2-3 cycles of doxorubicin (75 mg/m
2 ) and ifosfamide (6 g/m2 ) followed by radiotherapy of 28 Grays (Gy) administered as 8 fractions of 35 Gy) and 33 patients received radiotherapy alone. R0 resection rates and 3-year survival estimates were evaluated., Results: Median follow-up time was 37 months. The estimated 3-year overall and disease-free survival rates for the whole patient group were 79% (95% CI: 67.0-86.4) and 57.9% (95% CI: 46.3-69.0), respectively. The most common side effects were nausea and leucopenia. Three-year overall, disease-free, local recurrence-free and distant recurrence-free survival rates did not differ significantly. All patients except one underwent wide excision or compartmental resection. R0 resection rate for the whole patient group was 92.5% ( n = 62). Sites of progression were similar across both treatment arms., Conclusions: Preoperative hypofractionated radiotherapy alone or sequentially with chemotherapy result in high rates of limb salvage and acceptable toxicity. Our study results did not show a statistically significant treatment effect regarding survival and patterns of failure., Competing Interests: The authors declare no conflict of interest.- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.